This is not the most recent version of this material.
For an updated version, please see the relevant topic page.
Migraine: Draft Evidence Report
ICER’s Draft Evidence Report on erenumab for migraine, open to public comment until May 8, 2018. For more information on submitting a public comment, please visit our stakeholder engagement page.View All Materials on this Topic or Go Back to View More Materials